Latham & Watkins Represents AtaiBeckley in Sale to Lilly

Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI) have announced a definitive agreement for Lilly to acquire AtaiBeckley, a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments.

Latham & Watkins LLP represents AtaiBeckley in the transaction with a team led by corporate partners Scott Shean, Nathan Ajiashvili, Charles Ruck, and Brian Umanoff, with associates Abby Timmons, Jordan Freisleben, Ashley Campfield, and Chloe Barr. Advice was also provided on FDA/regulatory matters by partners John Manthei and Elizabeth Richards; on healthcare matters by partner Betty Pang; on public company representation matters by counsel Irina Yevmenenko, with associate Cat Cohen; on executive compensation, employment, and benefits matters by partner David Della Rocca and counsel Laura Szarmach, with associates Amal Rafiq and Heather Jäger; on antitrust matters by partners Patrick English and Héctor Armengod, with associates Nathaniel Amann, Alec Dougherty, and Julia Weber; on tax matters by partner Rene de Vera, with associate Sam Yang; and on data privacy and cybersecurity matters by partner Heather Deixler and counsel Oliver Mobasser, with associates Ben Leigh and Stuart Cobb.